Potency of a novel multi-epitope vaccine against foot-and-mouth disease type Asia 1 in guinea pigs
SHAO Jun-jun, WANG Jing-feng, GAO Shan-dian, LIN Tong, CHANG Hui-yun
State Key Laboratory of Veterinary Etiological Biology, National Foot and Mouth Disease Reference Laboratory, Engineering Research Center of Biological Detection of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China
Abstract:The potency of an improved recombinant multi-epitope vaccine against FMDV type Asia1 was evaluated in this study. A multi-epitope gene based on FMDV type Asia1 was designed and a recombinant expression plasmid (pRE-oIgG) was constructed. The proteins, RE-oIgG and 3D were expressed in E. coli cells and purified with Ni-NTA agarose resin by affinity chromatography. The proteins, RE-oIgG, 3D and RE-oIgG plus 3D, were emulsified in an oil adjuvant ISA 206. Twenty-five female guinea pigs were randomly divided into five groups and intramuscularly vaccinated for with RE-oIgG, 3D, RE-oIgG plus 3D, an inactivated FMDV vaccine (type Asia1), and PBS. All animals were vaccinated for two times. Anti-FMDV specific antibodies, neutralization antibodies, protection potency, and lymphoproliferation assay were detected by ELISA, virus neutrali-zation assay, challenge test, and flow cytometry, respectively. Results showed that RE-oIgG plus 3D elicited significant high-level anti-FMDV specific antibodies compared to RE-oIgG alone (P<0.05). All the vaccinated animals induced higher level lymphoproliferation responses in vitro except PBS. Both 3D alone and PBS produced the negligible neutralizing antibodies and anti-FMDV specific antibodies. RE-oIgG plus FMDV 3D not only elicited high levels of anti-FMDV neutralizing antibodies, but also induced significant lymphoproliferation responses. More importantly, RE-oIgG plus 3D conferred complete protection to guinea pigs against challenge with 1 000 GPID50. Interestingly, two of five vaccinated animals with 3D alone were full protected against challenge, and other three animals significantly showed a delay of 2-3 days in the onset of clinical signs. Therefore, we considered that RE-oIgG plus 3D induces strong humoral and cellular immune responses, which may be used for control and prevention of FMD in the future.
邵军军, 王景锋, 高闪电, 林彤, 常惠芸. Asia1型口蹄疫新型多表位疫苗免疫豚鼠的效力试验[J]. 中国人兽共患病学报, 2014, 30(7): 692-697.
SHAO Jun-jun, WANG Jing-feng, GAO Shan-dian, LIN Tong, CHANG Hui-yun. Potency of a novel multi-epitope vaccine against foot-and-mouth disease type Asia 1 in guinea pigs. Chinese Journal of Zoonoses, 2014, 30(7): 692-697.
[1]Doel TR. FMD vaccines[J]. Virus Res, 2003, 91(1):81-99. DOI:10.1016/S0168-1702(02)00261-7 [2]Thompson D, Muriel P, Russell D, et al. Economic coasts of the foot-and-mouth disease outbreak in the United Kingdom in 2001[J]. Rev Sci Tech, 2002, 21(3):675-687. [3]Chan EW, Wong HT, Cheng SC, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine[J]. Vaccine, 2000, 19(4-5):538-546. DOI:10.1016/S0264-410X(00)00186-9 [4]Zhang YL, Guo YJ, Wang KY, et al. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus[J]. Scand J Immunol, 2007, 65(4):320-328. DOI:10.1111/j.1365-3083.2007.01900.x [5]Garcia-Briones MM, Blanco E, Chiva C, et al. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D[J]. Virology, 2004, 322(2):264-275. DOI:10.1016/j.virol.2004.01.027 [6]Blanco E, Garcia-Briones M, Sanz-Parra A, et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth di-sease virus[J]. J Virol, 2001, 75(7):3164-3174. DOI:10.1128/JVI.75.7.3164-3174.2001 [7]Gerner W, Denyer MS, Takamatsu HH, et al. Identification of novel foot-and-mouth disease virus specific T-cell epitopes in c/c and d/d haplotype miniature swine[J]. Virus Res, 2006, 121(2):223-228. DOI:10.1016/j.virusres.2006.05.006 [8]Shao JJ, Wong CK, Lin T, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine[J]. Clin Vaccine Immunol, 2011, 18(1):143-149. DOI:10.1128/CVI.00236-10 [9]Yi JZ, Liu MQ, Zhu CZ, et al. Recombinant bivalent vaccine against foot-and-mouth disease virus serotype O/A infection in guinea pig[J]. Acta Biochim Biophys Sin (Shanghai), 2004, 36(9):589-596. DOI:10.1093/abbs/36.9.589 [10]Su C, Duan X, Wang X, et al. Heterologous expression of FMDV immunodominant epitopes and HSP70 in P. pastoris and the subsequent immune response in mice[J]. Vet Microbiol, 2007, 124(3-4):256-263. DOI:10.1016/j.vetmic.2007.04.030 [11]Rodriguez LL, Grubman MJ. Foot and mouth disease virus vaccines[J]. Vaccine, 2009, 27(4):D90-94. DOI:10.1016/j.vaccine.2009.08.039 [12]Rodriguez LL, Gay CG. Development of vaccines toward the global control and eradication of foot-and-mouth disease[J]. Expert Rev Vaccines, 2011, 10(3):377-387. DOI:10.1586/erv.11.4 [13]Collen T, Pullen L, Doel TR. T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model[J]. J Gen Virol, 1989, 70(Pt2):395-403. DOI:10.1099/0022-1317-70-2-395 [14]Patch JR, Pedersen LE, Toka FN, et al. Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by vaccination[J]. Clin Vaccine Immunol, 2011, 18(2):280-288. DOI:10.1128/CVI.00417-10